Posted on

AIkido Pharma Inc. Provides Update on Its Next-Generation Chemotherapeutic Treatment DHA-dFdC

Synthesis of Critical Chemical Intermediate for Drug Confirmed

Synthesis of Critical Chemical Intermediate for Drug Confirmed

PR Newswire

NEW YORK, Oct. 28, 2020

NEW YORK , Oct. 28, 2020 /PRNewswire/ — AIkido Pharma Inc. (Nasdaq: AIKI) (“AIkido” or the “Company”) today provided an update on its preclinical work on its next-generation chemotherapeutic, DHA-dFdC, and the solid lipid nanoparticle (SLN) drug delivery system to treat pancreatic cancer, which the Company has licensed from the University of Texas at Austin .

(PRNewsfoto/AIkido Pharma Incorporated)

Pancreatic cancer is the 4 th leading cause of cancer deaths in the US and, partly because most cases are diagnosed at an advanced stage, the 5-year overall survival rate for those cases has remained only around 3%. See Sci Rep 10, 7048 (2020) . The Company is developing its drug product as an orally administered second-line treatment to target advanced pancreatic cancer.

The Company confirmed this week the successful synthesis of a critical intermediate compound for DHA-dFdC. Purification and isolation of this key intermediate were also completed and verified. The Company is also in the process of optimizing the SLN delivery vehicle with respect to particle size and stability.

In addition, the Company recently expanded upon its agreement with Parimer Scientific to immediately begin manufacturing activities including the following:

  • Developing analytical methods for both raw materials and final drug product,
  • Producing an optimized process for batch scale-up of the drug,
  • Producing and delivering 20,000 mg of final drug product to be used in toxicology studies,
  • Performing initial short-term and long-term stability testing in the selected bulk container closure using ICH Q1A(R2) Stability Testing of New Drug Substances and Products,
  • Creating a drug substance reference standard, and
  • Establishing drug purity per the relevant FDA standards.

Under the expanded agreement, the final drug product will be manufactured using at minimum GLP practices per 21 CFR 58 and following the recommendations in the FDA’s ICH Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients.

Dr. Richard T. Pace , Principal Scientist at Parimer Scientific commented, “We are very gratified to have confirmed isolation of the crucial chemical intermediate for this drug.  These results strongly indicate that developing a scalable process for drug manufacture will be achievable.”

Anthony Hayes , CEO of AIkido stated, “These are the results we have been hoping for and they greatly increase my optimism about the scalability of this product.  We plan to rapidly develop the process of drug incorporation into the SLN delivery particles and start preliminary biological testing, which should begin this quarter.”

About AIkido Pharma Inc.

AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology company with a diverse portfolio of small-molecule anti-cancer therapeutics. The Company’s platform consists of patented technology from leading universities and researchers and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and Wake Forest University . Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). In addition, we are constantly seeking to grow our pipeline to treat unmet medical needs in oncology.

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company’s filings with the SEC, not limited to Risk Factors relating to its business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

Contact:

Investor Relations:

Hayden IR

Brett Maas, Managing Partner

Phone: (646) 536-7331

Email: brett@haydenir.com

www.haydenir.com

AIkido:

Phone: 212-745-1373

Email: investorrelations@aikidopharma.com

www.aikidopharma.com

 

 

CisionView original content to download multimedia: http://www.prnewswire.com/news-releases/aikido-pharma-inc-provides-update-on-its-next-generation-chemotherapeutic-treatment-dha-dfdc-301162021.html

SOURCE AIkido Pharma Inc.

News Provided by PR Newswire via QuoteMedia

Posted on

MPV announces conditional approval of its transaction with Entheon Biomedical Corp. by the CSE

MONTREAL, Oct. 28, 2020 (GLOBE NEWSWIRE) – MPV Exploration Inc. (“MPV” or the “Company”) is pleased to announce that further to its press releases dated July 2, 2020 and September 10, 2020 (the “ initial press releases ”), the Company has received conditional approval from the Canadian Securities Exchange (“ CSE ”) to list the resulting issuer’s shares (as defined below) for trading in accordance with to the Merger Agreement (the “  Merger Agreement   ”) dated June 30, 2020 and amended on October 9, 2020 between Entheon Biomedical Corp. (”  Entheon  “) and 1254912 BC Ltd. (”  Subco “), Whereby the Company will acquire all of the issued and outstanding securities of Entheon in exchange for shares of the Company (the”  Transaction  “).

In addition and as part of the Transaction, the Company will change its name from “MPV Exploration Inc.” to “Entheon Biomedical Corp.” (The ”  Name Change  “). Simultaneously with the Change of name and as part of the Transaction, the Company will also consolidate its issued and outstanding ordinary shares at the rate of one (1) ordinary share subsequent to the Consolidation for three (3) ordinary shares in circulation of the Company’s capital (the “  C onsolidation “). Fractional shares will not be issued as any fractional shares will be rounded to the nearest whole number. In addition, the number, exercise price or exchange basis of all Warrants will be adjusted, from time to time, to reflect the Three-for-One Consolidation.

Following the simultaneous completion of the Transaction, Name Change and Consolidation, the new CUSIP number for the ordinary shares of the resulting entity (the “  Shares of the resulting issuer ”) Will be 29383X103 and the new ISIN number will be CA29383X1033. The Company will announce the symbol on the CSE for the shares of the resulting issuer no later than the closing of the Transaction. Currently, a total of 18,105,514 common shares of the Company are issued and outstanding and following Consolidation, the Company will have approximately 6,325,160 common shares of the resulting issuer issued and outstanding (assuming the exercise of options held by the officers and directors of MPV immediately before the completion of the Transaction). Following completion of the Transaction and having given effect to: (i) the 29,845,805 Shares of the resulting issuer to be issued to former Entheon shareholders; and (ii) the 4,217,886 1 resulting issuer shares to be issued to Subco shareholders, as part of the Concurrent Broker-less Private Placement conducted by Subco (as further detailed in the initial press releases), the Company will then have approximately 40,388,851 shares issued and outstanding.

In connection with the Consolidation, the shares of the resulting issuer after the Consolidation will be transferred to the registered shareholders of the Company by the Company’s transfer agent, Computershare Investor Services Inc. The Company expects the date of entry into effect. effect of the Consolidation and of the Name Change will take place on the date of completion of the Transaction.

Additional disclosure

Trading in the Company’s common shares was halted by the CSE on July 2, 2020 following the announcement of the merger agreement and will remain so until trading resumes after approval is obtained. final of the CSE.

For more information on the Transaction, please see the initial press releases. The Company will issue further press releases regarding the Transaction as the information becomes available.

About Entheon  Biomedical  Corp.

Entheon is a privately-held biotechnology research and development company engaged in the development and commercialization of a portfolio of safe and effective psychedelic therapeutics based on dimethyltryptamine (“DMT products”) for the treatment of substance abuse disorders and the use of substances. Subject to obtaining all required regulatory approvals and permits, Entheon intends to generate revenue through the sale of its DMT products to licensed physicians, clinics and psychiatrists in the United States, certain countries of the European Union and across Canada.

For more information on the Company or  on  Entheon, please visit:

MPV Exploration  Inc.
Jean-Francois Perras, President and Chief Executive Officer
Telephone: (514) 667-7171

Entheon  Biomedical  Corp.
Timothy Ko, CEO and Director
Phone: +1 (604) 562-3932
info@entheonbiomedical.com
https://entheonbiomedical.com/

Forward-looking statements

This press release contains forward-looking statements within the meaning of applicable securities laws. These statements relate to future events or future results. All statements other than those relating to historical facts may be informative or forward-looking statements. More particularly and without limitation, this press release contains forward-looking information and statements concerning the conclusion of the Transaction and the concomitant financing and the conditions relating thereto, the deadlines for the receipt of regulatory approvals, from the shareholders and the stock exchange as well as future plans and objectives of the Combined Company and others. Forward-looking information and statements are based on certain expectations and assumptions made by the management of the Company. As a result, no assurance has the effect that the proposed Transaction or related matters will be completed as advertised or even at all. Although the management of the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on them as there is no assurance that they will be correct.

Forward-looking information and statements are presented for informational purposes regarding current expectations and management’s plans for the future of the Company. Readers are cautioned that reliance on statements and information may not be appropriate for other purposes such as investment decisions. The fact that statements and information relate to future events involves certain risks and uncertainties. Actual results could be materially different from anticipated results due to a number of factors and risks. These may include, among others, the ability of the Company to continue its activities in the eventuality  or the Transaction would not take place to continue to operate its business, to conclude the concomitant financing or to obtain the approvals and authorizations required in order to conclude the Transaction as presently described. Therefore, the reader is cautioned not to place undue reliance on depressed-looking in this release. The reader is also cautioned not to consider the risk factors described herein as being exhaustive. Forward-looking statements and information contained in this press release are made as of this date and no commitment is made to release any update or revise forward-looking statements as a result of new information or future events unless required. under applicable securities law.

The Canadian Securities Exchange and the Information Services Provider have not reviewed and do not accept responsibility for the accuracy or adequacy of this version.

______________________
1  Includes 100,000 shares of the resulting issuer as well as 100,000 intermediation units (the “Finding Units”) that were issued as part of the simultaneous broker-less private placement conducted by Subco. Please note that the amount of intermediation units was incorrectly stated at 37,500 in the press release of September 9, 2020 (and its corresponding English press release of September 19, 2020).

Posted on

MindMed Files Final Prospectus In Connection With Bought Deal Equity Financing

FINANCING TO SUPPORT THE DEVELOPMENT OF MINDMED’S GROWING PIPELINE OF PSYCHEDELIC INSPIRED MEDICINES AND EXPERIENTIAL THERAPIES

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

TORONTO, Oct. 27, 2020 /CNW/ — Mind Medicine (MindMed) Inc. (NEO: MMED) (OTCQB: MMEDF) (“MindMed” or the “Company“) is pleased to announce that further to its previously announced offering (the “Offering“), it has filed a final short form prospectus (the “Prospectus“) with the securities commissions or similar authorities in each province of Canada, other than Québec. Pursuant to the underwriting agreement with Canaccord Genuity Corp. (the “Underwriter“), the Underwriter has agreed to purchase, as sole bookrunner and underwriter, 23,810,000 units of the Company (the “Units“), on a “bought deal” basis, at a price per Unit of $1.05 CAD (the “Issue Price“) for gross proceeds of $25,000,500.

The Company has also granted the Underwriter an over-allotment option to purchase up to an additional 15% of the Units at the Issue Price, exercisable in whole or in part, at any time on or prior to the date that is 30 days following the closing of the Offering. If this option is exercised in full, an additional $3,750,075 will be raised pursuant to the Offering and the aggregate proceeds of the Offering will be $28,750,575.

Each Unit will be comprised of one subordinate voting share of the Company (each, a “Subordinate Voting Share“) and one-half of one Subordinate Voting Share purchase warrant (each whole warrant, a “Warrant“). Each Warrant shall entitle the holder thereof to purchase one Subordinate Voting Share at an exercise price of $1.40, for a period of 36 months following the closing of the Offering.

The Company intends to use the net proceeds of the Offering for investment in its research and clinical development initiatives, including its 18-MC addiction treatment program derived from the psychedelic ibogaine, lysergic acid diethylamide (LSD) microdose program for Adult ADHD, Project Lucy focused on LSD experiential therapy for anxiety disorders, University Hospital Basel Liechti Lab research and development collaboration, NYU Langone Health Psychedelic Medicine Research Training Program, and for general working capital and corporate development purposes.

The Offering is scheduled to close on or about October 30, 2020 and is subject to certain conditions including, but not limited to, the receipt of all necessary approvals.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the United States Securities Act of 1933, as amended, and applicable state securities laws.

The Prospectus containing important information relating to these securities has been filed with securities commissions or similar authorities in each province of Canada, other than Québec and may be subject to amendment. A copy of the Prospectus can be obtained under the Company’s corporate profile on SEDAR at www.sedar.com.

About MindMed

MindMed is a psychedelic medicine biotech company that discovers, develops and deploys psychedelic inspired medicines and experiential therapies to address addiction and mental illness. The Company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT and an Ibogaine derivative, 18-MC. The MindMed team brings extensive biopharmaceutical experience to the Company’s groundbreaking approach to developing the next generation of psychedelic inspired medicines and experiential therapies.

MindMed trades on the Canadian NEO Exchange under the symbol MMED. MindMed is also traded in the United Statesunder the symbol MMEDF and in Germany under the symbol MMQ. For more information: http://www.mindmed.co/

Forward-Looking Statements

Certain statements in this news release related to the Company are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the closing of the Offering, regulatory approvals and the intended use of proceeds of the Offering. There are numerous risks and uncertainties that could cause actual results and MindMed’s plans and objectives to differ materially from those expressed in the forward-looking information. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.

Media Contact: mindmed@crosscutstrategies.com

Investor Relations: investors@mindmed.co

SOURCE Mind Medicine (MindMed) Inc.

Posted on

NEONMIND MANUFACTURES 4 SUPERFOOD MUSHROOM COFFEES

Vancouver, B.C. – October 27, 2020: Better Plant Sciences Inc. (CSE: PLNT) (OTCQB: VEGGF) (FSE: YG3) (“Better Plant”) or (the “Company”)  is pleased to announce that its majority owned subsidiary NeonMind Biosciences (“NeonMind”) has completed an initial production run of all four of its Ayurvedic, functional mushroom coffees.

 

“With this production run successfully completed, we are now prepared to begin consumer testing. We are also lining up distribution and are preparing to begin tests for digital  marketing for the website prior to its launch,” said Penny White, CEO of Better Plant. “We are excited to be able to fulfill the growing consumer appetite for functional food products that promote good health.”

 

Functional foods are food that are demonstrated to have physiological benefits and/or reduce the risk of chronic disease beyond just providing nutrition alone.

 

This production run includes four unique SKUs, which are all infused with Ayurveda botanicals:

 

Two instant superfood mushroom coffee blends for on-the go:

 

  • Rest Blend: Contains Lion’s Mane, Reishi, Ashwagandha and Turmeric
  • Energize Blend: Contains Turkey Tail, Cordyceps, Holy Basil and Moringa

 

Two traditional roasted superfood mushroom coffee blends:

 

  • Focus Blend (Dark Roast): Contains Lion’s Mane, Reishi, Gotu Kola, Brahmi
  • Protect Blend (Medium Roast): Turkey Tail, Cordyceps, Moringa and Amla

 

“When selecting partners such as a co-packer for functional food production, it is crucial to find alignment on safety, nutrition, quality and values,” said Bhavna Solecki, Director of Research and Product Development for Better Plant. “Production facilities should have suitable techniques, methods, and tools, to keep and enrich the nutritive values and bioactivity of the products, as well as  be able to propose future directions for food analytical methodologies to refine the process of sorting, grinding, conveying, processing and packaging systems. They must also be able to provide nutritional facts and quality of food and contents of nutrients and bio active components using third party analysis”

 

Each batch also goes through third party microbial testing with a certificate of analysis issued by the facility to enhance the homogeneity and stability of the final product for storage and shelf life.

 

Grand View Research reported in 2019 that the functional foods market is expected to reach USD $275.77 billion by 2025.

 

About NeonMind Biosciences Inc. 

 

NeonMind is engaged in research and development of products that use medicinal and psychedelic mushrooms to optimize human health and performance. The company is launching a line of coffees infused with health optimizing medicinal mushrooms including reishi, cordyceps, lion’s mane and turkey tail mushrooms. NeonMind is also engaged in research into developing a psilocybin (psychedelic mushroom) based product for weight loss and plans to soon begin preclinical trials to study its pending psychedelic medicine patents. NeonMind owns 18% of Translational Life Sciences Inc. Better Plant Sciences owns approximately 50% of the issued and outstanding stock of NeonMind.

 

About Better Plant Sciences Inc.


Better Plant develops and acquires intellectual property and other assets related to plant-based products and therapeutics. Through its integrated business model, Better Plant develops, manufactures, markets, sells and distributes plant-based products. It owns over 400 proprietary product formulas.  It operates websites and sells through eCommerce, Amazon and through a retail store network over 150 plant based products for body, baby and home under the brands JUSU, Urban Juve and Wright & Well. Its 50% majority-owned subsidiary NeonMind Biosciences Inc. is launching a line of coffees infused with health optimizing medicinal mushrooms including reishi, cordyceps, lion’s mane and turkey tail mushrooms. NeonMind is also engaged in research into developing a psilocybin (psychedelic mushroom) based product for weight loss and has applied for Health Canada approval to begin preclinical trials to study its pending psychedelic medicine patents.

For more information about Better Plant, visit www.betterplantsciences.com or follow @betterplantsciences on Instagram.

 

Investor Relations Contact:

Penny White, President & CEO

Ali Dumanski, Investor Relations

invest@betterplantsciences.com

1-833-514-2677

The Canadian Securities Exchange has not reviewed, approved or disapproved the contents of this news release.

 

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking information and statements (collectively, “forward looking statements”) under applicable Canadian securities legislation.  Forward-looking statements are necessarily based upon a number of estimates, forecasts, beliefs and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements.  Such risks, uncertainties and factors include, but are not limited to: risks related to the development, testing, licensing, brand development, availability of packaging, intellectual property protection, reduced global commerce and reduced access to raw materials and other supplies due to the spread of COVID-19, the potential for not acquiring any rights as a result of the patent  application and any products making use of the intellectual property may be ineffective or the company may be unsuccessful in commercializing them; and other approvals will be required before commercial exploitation of the intellectual property can happen.  Demand for the company’s products, general business, economic, competitive, political and social uncertainties, delay or failure to receive board or regulatory approvals where applicable, and the state of the capital markets.  Better cautions readers not to place undue reliance on forward-looking statements provided by Better, as such forward-looking statements are not a guarantee of future results or performance and actual results may differ materially. The forward-looking statements contained in this press release are made as of the date of this press release, and Better expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

Posted on

ATAI Life Sciences Announces Neuronasal Completes Pilot Study, Receives IND Clearance to Continue into Phase I Trials of mTBI Therapeutic

NEW YORK, Oct. 27, 2020 /PRNewswire/ — ATAI Life Sciences (“ATAI” or the “Company”), a global biotechnology company developing psychedelic and non-psychedelic compounds for various mental health indications, today announced that Neuronasal Inc. (“Neuronasal”) has completed its pilot study intended to show nose to brain delivery of N-acetylcysteine (NAC) in healthy volunteers. Additionally, Neuronasal has been granted Investigational New Drug (IND) clearance by the FDA to continue phase I clinical trial development in partnership with ATAI.

Concussions and other forms of mTBI represent a significant unmet medical need. With no currently approved treatments, patients often suffer acute symptomatology including headache, nausea, fatigue, depression, anxiety and irritability. In fact, approximately half of the 2.5 million people who are concussed every year in the United States alone develop long-term cognitive impairment. Also, the ongoing NINDS-funded TRACK-TBI initiative has recently revealed that concussion is associated with substantial increases in the rates of major depressive disorder, post-traumatic stress disorder, and other psychiatric and non-psychiatric conditions.

Typically, concussions are the result of physical trauma that disrupts brain tissue and blood supply, followed by focal vascular leakage, inflammation, the formation of reactive oxygen species (ROS) and the release of excessive amounts of glutamate. This, in turn, exhausts the pool of intracellular glutathione in brain and induces glutamate-mediated neuro-excitotoxic damage. In more severe cases, neuronal atrophy and necrosis can occur as well.

Neuronasal’s potentially ground-breaking proprietary treatment includes the intranasal delivery of low doses of N-acetylcysteine (NAC) to patients with acute mild traumatic brain injury (mTBI). NAC is a well-established compound that has been used safely for decades, mostly as a mucolytic and to treat acute paracetamol intoxication. NAC is stimulating the synthesis of glutathione that is the most abundant endogenous antioxidant, known to prevent oxidative damage to cellular components. In addition, NAC itself has direct antioxidant, anti-inflammatory, and free radical scavenging effects. Finally, NAC acts as an inhibitory glutamatergic modulator. All of these mechanisms are important in the context of mTBI.

NAC has the potential to disrupt the deleterious chain of events following mTBI. In soldiers exposed to explosive blast injury the probability of symptom resolution at 7 days increased from 41.9 to 86.2% when receiving NAC treatment within 24 hours post-blast.

Neuronasal’s intranasal approach enables direct nose-to-brain delivery, allowing for significantly lower doses and outpatient treatment. Given its apparent efficacy in disrupting the underlying neurochemical cascade, intranasal NAC has the potential to induce a fundamental shift in the natural course of the condition for hundreds of thousands of people.

“mTBIs are more than just uncomfortable and can result in everything from depression and anxiety to cognitive decline when left untreated,” said ATAI’s Chief Scientific Officer, Srinivas Rao. ”By developing an early intervention, we stand to disrupt a potentially disastrous disease trajectory.”

“We are pleased with our pilot trial results.” said Thomas Bradshaw, CEO of Neuronasal. “Our team is excited to move into Phase I clinical development with the support of the team at ATAI.”

About ATAI Life Sciences

ATAI is a biotechnology company founded in 2018 in response to the clear and growing unmet needs of mental health patients worldwide. ATAI acquires, incubates and efficiently develops innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders. ATAI’s business model combines funding, technology, scientific and regulatory expertise with a focus on psychedelic therapy and other drugs with differentiated safety and therapeutic potential. By pooling resources and best practices ATAI has been able to responsibly accelerate the development of new medicines across its business entities, aiming to effectively treat and ultimately heal mental health disorders. ATAI’s vision is to bridge the gap between what the mental healthcare system currently provides and what patients need. ATAI is headquartered in Berlin, with offices in New York and San Diego. For more information, please visit www.atai.life.

Media Contact: 
Anne Donohoe
KCSA Strategic Communications
Phone: +1 (212) 896-1265
Email: ATAI@KCSA.com

SOURCE ATAI Life Sciences

Posted on

Canada Calls for Reformative Action in the Opioid Crisis

Worldwide, substance use disorders are on the rise, causing a high financial and social cost, yet the current model helps only a fraction of those suffering.

Substance use disorders have exacerbated overcrowding of the healthcare system, which has forced policymakers around the world to seek out more modern and compassionate healthcare alternatives and preventative harm-reduction measures.

Canada appears to be taking a progressive yet patchworked community healthcare approach to alleviating the current opioid and substance-use crisis. At the Federal level, Health Canada appears to be taking promising steps toward easing the surge in pandemic-related relapse rates and the troubling rise in overdose deaths that reached pandemic proportions before the arrival of COVID-19.

In February 2017, the Federation of Canadian Municipalities’ (FCM) Big-City Mayors’ Caucus (a collective of representatives from 22 of Canada’s biggest cities) launched a task force dedicated to curate best practices around substance use to prevent deaths and save more lives. This initiative has put together a comprehensive list of recommendations that call for a coordinated, nationwide approach requiring actions by all government levels.

To execute these proposed recommendations, the FCM recommends further action at the community-level would bolster the success of Canada’s drug strategy four-pronged approach: harm reduction, treatment, prevention and enforcement. As an alternative, they suggest replacing incarceration for possession of illegal substances with increased access to health care, treatment and social services. However, there is considerable debate regarding the efficacy of such a wide-scale change of legislation, suggesting that more research and discourse are first required.

Nevertheless, in addition to these efforts, Health Canada has released a letter that demands government ministries “conduct a thorough assessment of any barriers to access medicines that could contravene public health advice for social distancing and self-isolation, when appropriate.”

Photo by Nico Smit on Unsplash

Multiple Barriers to Substance Use Disorder Treatments

As highlighted in at least one past entry, the barriers vary and come loaded with socio-economic nuance. They include:

  • Current regulations around illegal substances
  • Restrictions imposed by medicated-assisted treatment protocols
  • Costs associated with traditional treatment models
  • Lack of effectiveness associated with standard treatment models

Even using the “most effective” legal methods of treating alcohol dependence, long-term patient outcomes are limited, with most patients relapsing the first year following a purely psychosocial based intervention. It is usual for a patient to require repeated stays at 90-day treatment centres. Without insurance coverage, the modality is too costly for the average citizen to afford.

In Canada, programs exist covered by provincial health care; however, patients can find themselves wait-listed for treatment when demand for detox and in-patient programs rises. In the context of these harsh realities, many researchers are focused on drug discovery to find modern efficacious uses for known or overlooked psychedelic chemical compounds that may provide long-term symptom relief for specific use-cases.

Photo by Priscilla Du Preez on Unsplash

Why Consider Psychedelics for Substance Use Disorders?

There are many programs in place to address substance use disorders (SUDs), including government-run programs, social programs run by non-government entities, and religious programs.

As a member of Entheon’s influential team of scientists and researchers, Dr. Christopher Gondi, Ph.D., M.Sc. seeks to explore the therapeutic benefits of psychedelic substances in helping patients reconcile their views and past traumas. From his lab at the University of Illinois College of Medicine Peoria, Dr. Gondi shared with us some insight into why religious-leaning programs like Alcoholics Anonymous (AA) and Narcotic Anonymous (NA), which require individuals to surrender to a higher power, are perceived to have a higher success rates (actual rate is challenging to determine due to the insistence on anonymity) than non-religious detox programs.

“Those programs help more than the structure where you go through a detox period for some time and then you’re kicked out. [Those patients] come back. Why? Because they have not reconciled their deep-seated emotional trauma and emotional need that needs to be addressed. For some reason – and I have no answer for this – the touching on the spiritual needs of an individual is something that psychedelics have helped.”

Indeed, one of tne of the naturally-occurring psychedelic molecules Entheon Biomedical is studying, called DMT or N, N-Dimethyltryptamine, is given the moniker “the spirit molecule.”

Johns Hopkins Magazine recently resurfaced findings from a DMT survey study, noting that:

“The vast majority of the respondents said DMT brought them into contact with a “conscious, intelligent, benevolent, and sacred entity,” most commonly described as a “being” or “guide” in an interaction that oozed joy, trust, love, and kindness. Eighty percent reported that the experience had fundamentally altered their perception of reality, and 72% said that the entity continued to exist after the experience “in a different plane of reality.” Perhaps most startling was that more than half of those who had previously self-identified as atheists—28% of the sample—described some type of belief in a higher power or God after taking DMT, according to Griffiths, director of the Johns Hopkins Center for Psychedelic and Consciousness Research.”

The advent of psychedelic-assisted therapy is a significant moment in human history, and the fact that it may be sparking an entheogenic-related religious curiosity seems to be part of the course with these powerful substances. However, insurance companies are not about to cover substances that are not legal, even if they result in a longer-lasting reduction of drug-seeking and drug-taking behaviours.

Photo by Alexis Mette on Unsplash

Who Will Prevail in Helping to Make Psychedelics Accessible to Patients in Canada?

We want to highlight two groups taking unique approaches to entheogenic (psychedelic) drug reform in Canada.

TheraPsil is a non-profit organization that supports Canadians in palliative care and experiencing end-of-life distress to exercise their charter right to seek compassionate treatment using psilocybin through an application for exemption of section 56(1) of the controlled substances and drug act (CDSA).

The palliative care patient’s use case is admittedly different from that of drug-dependent individuals, yet both sets of people are looking for some of the same things, relief from trauma being part of that.

On August 4th, 2020, four Canadians suffering from end-of-life distress became the first individuals to access an exemption to access psilocybin therapy legally. Today, the organization has secured six exemptions and is now asking Canada’s Ministry of Health to review physician requests to use psilocybin to better understanding patient outcomes. Not only has Federal Minister of Health Patty Hajdu been granting these exemptions, but she has also gone on record about her “open(ness)” to drug decriminalization.

Dr. Ryan Patchett-Marble from Marathon, Ontario (Thunder Bay district), is one such physician who recently told a local media outlet his reason for applying for the exemption through TheraPsil. “The reason I think it’s important for physicians or therapists themselves to have experiential training, this is not like when I prescribe antibiotics for an ear-tract infection, I don’t need experience with the antibiotic, this is prescribing,” he said. “This is more akin to a guide. You want the guide to have personal experience in what they are guiding you in.”

In a separate motion that could potentially increase access to entheogens to all Canadians, a petition to decriminalize plant medicines in Canada was presented in the House of Commons by Paul Manly MP on September 30th, 2020. The Canadian government has 45-days from then to respond to the petition from the Canadian Psychedelic Association that is now undersigned by 15,000 Canadians.

Posted on

COMPASS Pathways plc to ring Nasdaq Stock Exchange opening bell in celebration of its successful $146.6 million IPO

COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced that it will ring the Nasdaq Stock Exchange opening bell today, in celebration of its recently completed initial public offering.

George Goldsmith, CEO and Co-founder, COMPASS Pathways, will be joined by members of the COMPASS team for the virtual ceremony, which will begin at approximately 9.20am Eastern Time, and can be viewed live at https://livestream.com/nasdaq/live and on the Nasdaq MarketSite Tower at 43rd Street and Broadway, New York, NY. The bell ringing will take place at 9.30am Eastern Time, signifying the start of the day’s trading session.

George Goldsmith said, “I am honoured to be ringing the Nasdaq opening bell on behalf of everyone at COMPASS Pathways. We are on a mission to transform mental health care and I know that every member of our 60-person team shares our strong sense of purpose and our determination to reduce the personal and economic burden of mental health suffering.

“We have a big vision. We see a world of mental wellbeing, a world in which mental health isn’t simply the absence of mental illness but the ability to flourish. Our first priority is to bring our psilocybin therapy to some of the millions of people who suffer with treatment-resistant depression. We want to develop new models of care, supported by evidence from clinical trials and in the real world.”

 

About COMPASS Pathways

COMPASS Pathways plc (Nasdaq: CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. We are pioneering the development of a new model of psilocybin therapy, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has been designated a Breakthrough Therapy by the US Food and Drug Administration (FDA), for treatment-resistant depression (TRD), and we are currently conducting a phase IIb clinical trial of psilocybin therapy for TRD, in 20 sites across Europe and North America. We are headquartered in London, UK, with offices in New York, USA. Our vision is a world of mental wellbeing. www.compasspathways.com

 

Forward-looking statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. In some cases, forward-looking statements can be identified by terminology such as “may”, “might”, “will”, “could”, “would”, “should”, “expect”, “intend”, “plan”, “objective”, “anticipate”, “believe”, “contemplate”, “estimate”, “predict”, “potential”, “continue” and “ongoing,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond COMPASS’s control and which could cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by these forward-looking statements.

These risks, uncertainties, and other factors include, among others: preclinical and clinical development is lengthy and uncertain, and therefore our preclinical studies and clinical trials may be delayed or terminated, or may never advance to or in the clinic; and those risks and uncertainties described under the heading “Risk Factors” in COMPASS’s Prospectus filed with the US Securities and Exchange Commission (SEC) on 21 September 2020 and in subsequent filings made by COMPASS with the SEC, which are available on the SEC’s website at www.sec.gov. Except as required by law, COMPASS disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on COMPASS’s current expectations and speak only as of the date hereof.

 

Enquiries

COMPASS Pathways
Tracy Cheung, tracy@compasspathways.com, +44 7966 309024
Amy Lawrence, amy@compasspathways.com, +44 7813 777919

Westwicke (for investor enquiries)
Stephanie Carrington, stephanie.carrington@westwicke.com, +1 646 277 1282

Posted on

HAVN LIFE SCIENCES EARNS HEALTH CANADA APPROVAL FOR NATURAL HEALTH PRODUCT FORMULATIONS

The initial six approved formulations were developed to enhance human performance and cognitive health

Vancouver, BC – Havn Life Sciences Inc. (CSE : HAVN) (FSE : 5NP) (the “Company” or “Havn Life”),  a biotechnology company focused on unlocking human potential using evidence-informed research and developing standardized psychoactive compounds derived from plants and fungi, is pleased to announce it has received approval from Health Canada for six of its natural health product formulations.

“We are seeing tremendous consumer demand for natural health products that have the ability to enhance human performance and cognition. Earning these approvals has put us on a path to deliver products by early 2021 and also validates the science behind Havn Life’s formulations,” said Gary Leong, Chief Scientific Officer of Havn Life. “We are focused on harnessing the power of these plants and fungi and to scale our process effectively to meet the needs of researchers and consumers alike.”

These formulations are the first of what will be a range of natural health products that Havn Life is developing for launch in 2021. According to sales aggregator SPINS, Amid the COVID-19 pandemic and last year’s flu season, consumer demand for products that support immunity and focus has also skyrocketed.

Each of these initial  products  is designed with human performance in mind. The formulations include a mushroom mix containing lion’s mane, chaga, cordyceps and reishi that addresses cognitive function and regulation, human performance and immunity.

The five other individual formulations each focus on one key active ingredient that aids in stress management, memory and focus.

According to a 2020 study by Grandview Research, the global dietary supplements market size was estimated at USD $123.28 billion in 2019 and is projected to continue to grow.

“Factors, such as rising health concerns and the changing lifestyles and dietary habits have been driving the product demand,” the study notes.

On Behalf of The Board of Directors
Tim Moore
Chief Executive Officer

About Havn Life Sciences Inc.

Havn Life Sciences is a biotechnology company on a mission to unlock human potential using evidence-informed research. The Company is focused on standardized, quality-controlled extraction of psychoactive compounds from plants and fungi, and the development of natural health care products from non-regulated compounds. Learn more at: havnlife.com and follow us on Facebook, Twitter and Instagram.

Connect

Investor Relations
ir@havnlife.com
604 (687)-7130

Facebook: @havnlife
Twitter: @havnlife
Insta: @havn.life
LinkedIn: @Havn Life

Media Contact
Brittany@exvera.com
778-238-6096

 

LinkedInFacebookTwitterEmailShare
Posted on

Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19

TORONTO, Oct. 26, 2020 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration (“U.S. FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19. The Company has committed to ten clinical sites across Florida, Texas, Nevada, Arizona and California, and it is estimated that over 200 patients will have completed the Study for the interim analysis by the end of December 2020. The interim analysis will determine the better performing Bucillamine dose arm for the remainder of the trial and future complementary studies evaluating it in more severe cases, thus making Bucillamine a potential treatment option.

“We are one of a few life sciences companies evaluating an investigational drug in a Phase 3 clinical trial for COVID-19 and with the rising prevalence of cases throughout the U.S., we are confident that our targets will be achieved to support the potential FDA approval and commercialization of Bucillamine for the treatment of the virus,” said Michael Frank, Revive’s Chief Executive Officer.

The recent publication of the potential of N-acetyl-cysteine (“NAC”) in the treatment of COVID-191 serves as further validation for Bucillamine. NAC has been shown to significantly attenuate clinical symptoms in respiratory viral infections in animals and humans, primarily via donation of thiols to increase antioxidant activity of cellular glutathione.

In comparison, Bucillamine, with its well-established safety record in over 30 years of use in the treatment of rheumatoid arthritis, has been shown to be 16 times more potent as a thiol donor in vivo than NAC. Bucillamine also has the potential, via increasing glutathione activity and other antioxidant and anti-inflammatory activities,2 to lessen the destructive consequences of more advanced SARS CoV2 infections, and attenuate the clinical course of severe COVID-19.

About the Phase 3 Clinical Trial

The Phase 3 confirmatory clinical trial titled, “A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of Bucillamine in Patients with Mild-Moderate COVID-19”, will enroll up to 1,000 patients that will be randomized 1:1:1 to receive Bucillamine 100 mg three times a day (“TID”), Bucillamine 200 mg TID or placebo TID for up to 14 days. The primary objective is to compare the frequency of hospitalization or death in patients with mild-moderate COVID-19 receiving Bucillamine therapy with those receiving placebo. The primary endpoint is the proportion of patients meeting a composite endpoint of hospitalization or death from the time of the first dose through Day 28 following randomization. Efficacy will be assessed by comparing clinical outcomes (death or hospitalization), disease severity using the 8-category NIAID COVID ordinal scale, supplemental oxygen use, and progression of COVID‑19 between patients receiving standard-of-care plus Bucillamine (high dose and/or low dose) and patients receiving standard-of-care plus placebo. Safety will be assessed by reported pre-treatment adverse events and treatment-emergent adverse events (including serious adverse events and adverse events of special interest), laboratory values (hematology and serum chemistry), vital signs (heart rate, respiratory rate, and temperature), and peripheral oxygen saturation.

An interim analysis will be performed by an Independent Data and Safety Monitoring Board (“DSMB”) after 210 patients have been treated and followed up for 28 days after randomization. The better performing Bucillamine dose at the interim analysis will be selected and patients will then be randomized 2:1 to the selected Bucillamine dose or placebo. Additional interim analyses will be performed after 400, 600, and 800 patients have reached this same post-treatment timepoint. The independent DSMB will actively monitor interim data for the ongoing safety of patients and will recommend continuation, stopping or changes to the conduct of the study based on the interim analysis reports.

The Company is not making any express or implied claims that its product has the ability to eliminate or cure COVID-19 (SARS-2 Coronavirus) at this time.

Scientific Rationale of Bucillamine for COVID-19

Preclinical and clinical studies have demonstrated that reactive oxygen species contribute to the destruction and programmed cell death of pulmonary epithelial cells.3 N-acetyl-cysteine (NAC) has been shown to significantly attenuate clinical symptoms in respiratory viral infections in animals and humans, primarily via donation of thiols to increase antioxidant activity of cellular glutathione.4-7 Bucillamine (N-(mercapto-2-methylpropionyl)-l-cysteine) has a well-known safety profile and is prescribed in the treatment of rheumatoid arthritis in Japan and South Korea for over 30 years. Bucillamine, a cysteine derivative with two thiol groups, has been shown to be 16 times more potent as a thiol donor in vivo than NAC.2 The drug is non-toxic with high cellular permeability. The basis of the clinical study will analyze if Bucillamine has the potential, via increasing glutathione activity and other antioxidant and anti-inflammatory activity, to lessen the destructive consequences of SARS-CoV2 infection in the lungs and attenuate the clinical course of COVID-19.

About Revive Therapeutics Ltd.

Revive is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, and it is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the FDA such as Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease designations. Currently, the Company is exploring the use of Bucillamine for the potential treatment of infectious diseases, with an initial focus on severe influenza and COVID-19. With its recent acquisition of Psilocin Pharma Corp., Revive is advancing the development of Psilocybin-based therapeutics in various diseases and disorders. Revive’s cannabinoid pharmaceutical portfolio focuses on rare inflammatory diseases and the company was granted FDA orphan drug status designation for the use of Cannabidiol (CBD) to treat autoimmune hepatitis (liver disease) and to treat ischemia and reperfusion injury from organ transplantation. For more information, visit www.ReviveThera.com.

For more information, please contact:

Michael Frank
Chief Executive Officer
Revive Therapeutics Ltd.
Tel: 1 888 901 0036
Email: mfrank@revivethera.com
Website: www.revivethera.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.

Cautionary Statement

This press release contains ‘forward-looking information’ within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Revive’s current belief or assumptions as to the outcome and timing of such future events. Forward looking information in this press release includes information with respect to the Offering, including the intended use of proceeds. Forward-looking information is based on reasonable assumptions that have been made by Revive at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. Given these risks, uncertainties and assumptions, you should not unduly rely on these forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and Revive is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein. Reference is made to the risk factors disclosed under the heading “Risk Factors” in the Company’s annual MD&A for the fiscal year ended June 30, 2019, which has been filed on SEDAR and is available under the Company’s profile at www.sedar.com.

References

1. H Ibrahim et al, Therapeutic blockade of inflammation in severe COVID-19 infection with intravenous N-acetylcysteine., Clinical Immunology. Volume 219, October 2020, 108544.

2. LD Horwitz, Bucillamine: a potent thiol donor with multiple clinical applications, Cardiovasc Drug Rev. 2003 Summer;21(2):77-90).

3. S Ye et al, Inhibition of Reactive Oxygen Species Production Ameliorates Inflammation Induced by Influenza A Viruses via Upregulation of SOCS1 and SOCS3., American Society for Microbiology. 2015 Mar;89(5):2672-2683).

4. L. Carati et al, Attenuation of influenza-like symptomatology and improvement of cell-mediated immunity with long-term N-acetylcysteine treatment., Eur Respir J. 1997 Jul;10(7):1535-41).

5. M Mata et al, N-acetyl-L-cysteine (NAC) inhibit mucin synthesis and pro-inflammatory mediators in alveolar type II epithelial cells infected with influenza virus A and B and with respiratory syncytial virus (RSV)., Biochem Pharmacol. 2011 Sep;82(5):548-55.

6. D Ungheri et al, Protective effect of n-acetylcysteine in a model of influenza infection in mice., Int J Immunopathol Pharmacol. 2000 Sep-Dec;13(3):123-128.

7. RH Zhang et al, N-acetyl-l-cystine (NAC) protects against H9N2 swine influenza virus-induced acute lung injury., Int Immunopharmacol. 2014 Sep;22(1):1-8).

Posted on

Medspresso Launches Handcrafted Delights, CBD Infused Functional Foods

CAPE TOWN, SA / ACCESSWIRE / October 26, 2020 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) (“Wuhan” or the “Company”), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to share the following update regarding its Medspresso brand:

The company is pleased to announce the upcoming product launch of “Handcrafted Delights” by MedspressoTM. The new line entails medical-grade organic CBD infused treats made with top-shelf natural and organic ingredients ethically sourced from across Africa.

The Company’s mission these past few months was to design, formulate and bring to light, healthy and exceptional substitutes for guilty pleasures under this new sub-brand “Handcrafted Delights“.

This novel brand kicks-off with a range of unique, scrumptious and healthy cookies that will do justice to the tagline “The Good Kind of Guilty“. As good as coffee and cookies are together, this is just the beginning of many more CBD infused products currently under development by the “Foodicine team”.

This new brand will treat you with an initial 10 moreish cookies that are listed below. Each with the common benefits like reducing pain, boosting energy, relieving stress, providing antioxidants, and improving immunity. In addition, an assortment of vegan options is available:

  • Matcha & white choc chip
    • Benefits: boosts physical energy and brain function, and supports weight-loss.
  • Rooibos matcha & white choc chip (caffeine-free)
    • Benefits: Bone strengthening minerals, boosts brain function and supports weight-loss.
  • Dark choc macaron cookie
    • Benefits: Rich in vitamins and nutrients, lowers cholesterol and bone strengthening minerals
  • Chocolate crinkle cookie (Vegan)
    • Benefits: Rich in nutrients and polyphenols that improve blood flow to the brain
  • Blueberry crinkle cookie (Vegan)
    • Benefits: Rich in nutrients and antioxidants
  • Ginger & molasses (Vegan)
    • Benefits: Bone strengthening minerals, immune boosting, anti-inflammatory
  • Turmeric & agave (Vegan)
    • Benefits: Low glycemic index, immune boosting, anti-inflammatory
  • Rosewater & chamomile shortbread
    • Benefits: Helps with sleep, reduces inflammation, mood enhancer
  • Cappuccino shortbread
    • Benefits: Increases focus, boosts physical energy
  • Lavender & honey shortbread
    • Benefits: Helps with sleep, relaxing, rich in nutrients

*Benefits will vary from person to person.
*Each cookie will contain 5mg of medical-grade organic CBD.

All of our Handcrafted Delights will be available for sale on the Medspresso E-Commerce website medspresso.co very soon. You may subscribe to our newsletter to get timely updates and upcoming promotions.

About Wuhan General Group, Inc./ M2Bio Sciences, Inc

Wuhan General Group, Inc. through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company that researches, develops and commercializes a range of CBD-based products under Dr. AnnaRx™, Medspresso™ and Handcrafted Delights™ brands. In addition, its wholly-owned division, M2Bio is researching and developing indications for psilocybin new therapies that will help patients who suffer from addiction, mental illness, Alzheimer’s and Parkinson’s. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research and emerging technologies. Wuhan is listed and traded on the Over the Counter Bulletin Board of NASDAQ under the trading symbol “WUHN”.

For further information:

Publicly traded company (OTC PINK:WUHN)
Website: www.m2bio.co
E-mail:info@m2bio.co
Follow us on Twitter: https://twitter.com/m2bio
Follow us on Facebook: http://www.facebook.com/m2bio

Forward-Looking Statements:

Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.

SOURCE: Wuhan General Group, Inc./M2Bio Sciences, Inc

View source version on accesswire.com:
https://www.accesswire.com/612242/Medspresso-Launches-Handcrafted-Delights-CBD-Infused-Functional-Foods